January 2016 in “Refubium (Universitätsbibliothek der Freien Universität Berlin)” CAP7.1 is generally safe at 200 mg/m²/day, but can cause fatigue, nausea, hair loss, fever, and blood-related issues.
January 2004 in “Headache” Divalproex sodium significantly improved headaches in two-thirds of patients.
Combining ATRA with TPO-RA effectively stabilizes platelet counts in ITP patients.
5 citations
,
October 2024 in “Reumatismo” Upadacitinib significantly improved alopecia universalis and psoriatic arthritis in a patient.
November 2021 in “Research Square (Research Square)” 4-aminopyridine speeds up and improves skin wound healing.
December 2013 in “American journal of transplantation” The patient improved after antiviral treatment for a viral infection.
May 2022 in “The Journal of Sexual Medicine” Amoxapine may be effective for treating ejaculatory dysfunction.
1 citations
,
September 2022 in “Nepal journal of dermatology, venereology & leprology” Apremilast shows promise for several skin conditions but needs more research.
April 2024 in “JEADV clinical practice” Upadacitinib significantly improved both rheumatoid arthritis and alopecia areata in a patient.
May 2015 in “Cancer Research” A new treatment may prevent hair loss from chemotherapy by normalizing scalp cell death and reducing inflammation.
23 citations
,
December 2013 in “Molecular cancer therapeutics” Breast cancer treatments work better with AR activation, improving results and reducing side effects.
2 citations
,
September 2022 in “Annals of Oncology” Mirvetuximab soravtansine improves quality of life and reduces symptoms more than standard chemotherapy in ovarian cancer patients.
Upadacitinib effectively treated a patient with multiple inflammatory conditions.
October 2015 in “Elsevier eBooks” Pramipexole can cause side effects like dizziness, sleepiness, hallucinations, and low blood pressure, and it's important to educate patients and keep doses low.
September 2023 in “HAL (Le Centre pour la Communication Scientifique Directe)” Peptide nanoparticles can effectively deliver CRISPR-Cas9 to target KRAS mutations in cancer.
1 citations
,
August 2025 Drug repurposing can speed up and reduce costs in drug discovery, especially for cancer treatment.
33 citations
,
August 2024 in “Frontiers in Drug Discovery” Drug repurposing is a faster, cheaper way to develop new treatments using existing drugs.
February 2025 in “JDDG Journal der Deutschen Dermatologischen Gesellschaft” Deucravacitinib helped a man regrow hair and improve psoriasis.
1 citations
,
August 2021 in “Journal of The American Academy of Dermatology” Baricitinib was effective in treating both early and late onset alopecia areata.
7 citations
,
March 2023 in “JEADV. Journal of the European Academy of Dermatology and Venereology/Journal of the European Academy of Dermatology and Venereology” May 2025 in “Reactions Weekly” September 2024 in “Annals of Medicine and Surgery” Ritlecitinib is the first FDA-approved pill for treating significant hair loss in alopecia areata patients aged 12 and up.
December 2023 in “Reactions weekly” December 2023 in “Reactions weekly” September 2013 in “Reactions weekly”
10 citations
,
July 2022 in “Journal of Medicinal Chemistry” Adding a second method to PROTACs could improve cancer treatment.
11 citations
,
February 2022 in “JAAD case reports” Abrocitinib, a JAK inhibitor, may help treat atopic dermatitis and alopecia universalis together.
1 citations
,
July 2021 in “Current nanomedicine” The new gel formulation for Acitretin improves topical delivery and reduces oral toxicity.
January 2025 in “Recent Patents on Anti-Cancer Drug Discovery” The treatment showed high response rates and was well-tolerated, potentially extending patient survival.
November 2023 in “Children” Many pediatric epilepsy patients experience preventable severe adverse drug reactions, especially with certain medications and risk factors.